secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001326110-23-000063
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA rejects ImmunityBio's BLA for Anktiva (N-803) in bladder cancer; CRL cites manufacturing issues
--------------------------------------------------------------------------------

- FDA issued Complete Response Letter for Anktiva (N-803) + BCG in BCG-unresponsive NMIBC with CIS.
- Deficiencies relate to pre-license inspection of third-party contract manufacturing and additional CMC issues.
- No new preclinical or Phase 3 studies requested; FDA wants updated duration-of-response data and safety update.
- Executive Chairman provides $30M non-convertible debt financing (SOFR+8%, matures Dec 31, 2023).
- Partnering discussions for commercialization continue with a large biopharma; no assurance of completion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000132611023000063/0001326110-23-000063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000132611023000063/ibrx-20230509.htm
  HTML page:      https://secwatch.observer/filing/0001326110-23-000063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer